Comparing the current results to its competitors, Eagle Pharmaceuticals Inc reported Revenue decrease in the 2 quarter 2023 year on year by -12.8 %, slower than the combined decrease of the EGRX's competitors by -31.08 %, recorded in the same quarter.
despite revenue deterioration, Eagle Pharmaceuticals Inc increased its market share in this segment. company increased its market share in this segment to approximately 0.2 %.
April 15, 2024
Eagle Pharmaceuticals, a leading entity in the biomedicine space, is set to present supplementary data from their consequential Phase III trial at the revered ASPAN 2024 National Conference, scheduled to be orchestrated in Orlando, Florida. The eagerly awaited data will shed light on the sustained response of amisulpride, a burgeoning solution for the rescue treatment of postoperative nausea and vomiting (PONV).PONV, a commonly faced predicament for patients in the postoperative phase, often presents a significant barrier to swift recovery and overall patient comfort. Amisulpride’s potential in this regard, as demonstrated by Eagle Pharmaceutical s Phase III trial findings, marks a significant stride towar...
Publicly Traded Peers of Eagle Pharmaceuticals inc
Viatris Inc Share Performance
-0.18%
Over The Past 5 Days
Viatris Inc
Profile
Viatris Inc operates as a global pharmaceutical company, specializing in the development, manufacturing, and distribution of a wide range of generic and branded medicines, as well as biosimilars.
Medicinova Inc operates under a biopharmaceutical business model, primarily focused on the development and commercialization of innovative therapeutics. They strive to identify promising drug candidates with the potential to address unmet medical needs and advance them through clinical trials. By leveraging their research capabilities, strategic partnerships, and licensing opportunities, Medicinova Inc aims to bring these novel treatments to market and improve patient outcomes.
MannKind Corporation is a biopharmaceutical company that focuses on the development and commercialization of inhaled therapeutic solutions for patients with diseases such as diabetes and pulmonary arterial hypertension. The company's business model revolves around conducting research and development to create innovative inhalation therapies and gaining regulatory approvals for these treatments. They then market and distribute their products, either directly or through partnerships, to healthcare providers and patients worldwide.
Mallinckrodt Plc's business model revolves around acquiring and developing branded pharmaceutical products, as well as manufacturing and distributing generic and specialty pharmaceuticals. They aim to address unmet medical needs and improve patient lives through their diverse portfolio of drugs.
Lannett Company Inc operates as a pharmaceutical company, engaging in the development, manufacture, marketing, and distribution of generic pharmaceutical products. The company focuses on developing affordable alternatives to brand-name medications, offering a diverse portfolio of products across various therapeutic categories. Lannett's business model is centered around providing cost-effective generic medications to satisfy market demand and improve access to affordable healthcare options.
Sources:
Eagle Pharmaceuticals inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Eagle Pharmaceuticals inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
